Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA, United States.
Department of Surgery/Microbiology & Immunology, Winship Cancer Institute at Emory University, Atlanta, GA, United States.
Front Immunol. 2021 Aug 26;12:718621. doi: 10.3389/fimmu.2021.718621. eCollection 2021.
PI3K-δ and PI3K-γ are critical regulators of T-cell differentiation, senescence, and metabolism. PI3K-δ and PI3K-γ signaling can contribute to T-cell inhibition intrinsic mechanisms and regulation of suppressor cell populations, including regulatory T-cells and myeloid derived suppressor cells in the tumor. We examine an exciting new role for using selective inhibitors of the PI3K δ- and γ-isoforms as modulators of T-cell phenotype and function in immunotherapy. Herein we review the current literature on the implications of PI3K-δ and -γ inhibition in T-cell biology, discuss existing challenges in adoptive T-cell therapies and checkpoint blockade inhibitors, and highlight ongoing efforts and future directions to incorporate PI3K-δ and PI3K-γ as synergistic T-cell modulators in immunotherapy.
PI3K-δ 和 PI3K-γ 是 T 细胞分化、衰老和代谢的关键调节因子。PI3K-δ 和 PI3K-γ 信号通路可促进 T 细胞抑制的内在机制和抑制性细胞群体的调节,包括肿瘤中的调节性 T 细胞和髓源性抑制细胞。我们研究了一种使用选择性 PI3K δ-和 γ-同工型抑制剂作为免疫疗法中 T 细胞表型和功能调节剂的令人兴奋的新作用。本文综述了 PI3K-δ 和 -γ 抑制在 T 细胞生物学中的意义的现有文献,讨论了过继性 T 细胞疗法和检查点阻断抑制剂中存在的挑战,并强调了正在努力将 PI3K-δ 和 PI3K-γ 作为协同性 T 细胞调节剂纳入免疫疗法的方向。